Dipeptidyl peptidase-1 inhibitors in bronchiectasis.

Eur Respir Rev · 2025 · PMC12175074 · PMID 40533102

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

In asthma, as well as potential efficacy among patients displaying a neutrophilic endotype, the observed effects of DPP-1 on activating mast cell, lymphocyte and natural killer cell activation may be significant.

also in 13,097 other papers

nominally significantno p-value reported

There was also a nominally significant improvement in the Quality of Life-Bronchiectasis (QOL-B) respiratory score of 3.8 points in the 25 mg group compared to placebo at week 52 as well as improvements in the Bronchiectasis Exacerbation and Symptom Tool daily diary.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.